Hosted on MSN18d
AdvanCell raises $112m as radiopharma buzz continuesAdvanCell, an Australia-based radiopharmaceutical company, has raised $112m as investor interest in the radiopharma sector continues in 2025. The funding round was co-led by SV Health Investors, ...
Eli Lilly has begun the week with a bang. Early Monday morning, AdvanCell and OliX Pharmaceuticals put out news that the Big ...
AdvanCell is developing therapies to treat cancers including: prostate, skin, pancreatic, breast, bladder, colorectal, kidney ...
SYDNEY, February 03, 2025--(BUSINESS WIRE)--AdvanCell, a clinical-stage radiopharmaceutical company developing innovative cancer therapeutics, today announced the successful completion of an ...
Eli Lilly strengthens its pipeline with AdvanCell for targeted alpha therapies and partners with OliX to advance OLX75016 for ...
BRISBANE, Australia & INDIANAPOLIS--(BUSINESS WIRE)--AdvanCell, a clinical-stage radiopharmaceutical company specializing in targeted alpha therapies, today announced an expansion to the scope and ...
Eli Lilly inked two collaborations on Monday, one focused on cardiometabolic diseases with South Korea’s OliX Pharmaceuticals ...
AdvanCell, a clinical-stage radiopharmaceutical company developing innovative cancer therapeutics, today announced the successful completion of an oversubscribed US$112 million Series C financing.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback